Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments

Area of Science:

• Neuroimmunology
• Virology
• Pharmacovigilance

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare, severe demyelinating disease of the central nervous system.
• It results from reactivation of the JC virus (JCV), which is prevalent in the general population but typically asymptomatic.
• PML is strongly associated with immunosuppression, particularly in patients with HIV/AIDS, autoimmune diseases, or those receiving immunosuppressive therapies.

Purpose of the Study:

• To review the current understanding of PML pathophysiology, diagnosis, and risk factors.
• To highlight the association between specific biologic therapies and increased PML risk.
• To emphasize the urgent need for registries and observational studies to guide monitoring protocols.

Main Methods:

• Review of existing literature on PML, JCV, and associated risk factors.
• Analysis of PML incidence in relation to immunosuppressive conditions and therapeutic agents, including biologics like natalizumab and rituximab.
• Discussion of diagnostic approaches including neuroimaging, CSF JCV detection, and histology.

Main Results:

• PML risk is influenced by the underlying disease and specific immunosuppressive drugs.
• Biologic therapies, particularly natalizumab (for multiple sclerosis) and rituximab (in rheumatology), are associated with significant PML risk.
• Current monitoring strategies for natalizumab involve anti-JCV antibody titers and index values.

Conclusions:

• The pathophysiological mechanisms of PML are not fully understood, but immunosuppression is a key factor.
• The expanding use of biologics necessitates careful risk assessment and monitoring for PML.
• There is an urgent need for comprehensive registries and postmarketing studies to establish optimal monitoring protocols for PML risk stratification based on disease and treatment.